Postmarketing work is now part of user fee calculations and could add to the US Food and Drug Administration’s staffing needs, as well as increase industry’s costs, in the coming years.
The number of annual reports, postmarketing requirements and commitment reviews, as well as active REMS document reviews are among the highest by volume of the various workload categories across the prescription drug, generic drug and biosimilar user fee programs